Clinical trial
A Study of Galiximab + Rituximab Versus Rituximab + Placebo in Follicular…
NCT00363636 · Biogen, Industry · Terminated
Key facts
| NCT number | NCT00363636 |
|---|---|
| Title | A Study of Galiximab + Rituximab Versus Rituximab + Placebo in Follicular Non-Hodgkin's Lymphoma (NHL) |
| Official title | A Phase III, Randomized, Double-Blind Study of Galiximab in Combination With Rituximab Compared With Rituximab in Combination With Placebo for the Treatment of Subjects With Relapsed or Refractory, Follicular Non-Hodgkin's Lymphoma |
| Lead sponsor | Biogen, Industry |
| Status | Terminated |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Lymphoma, Non-Hodgkin's |
| Intervention type | Drug |
| Interventions | Galiximab in combination with rituximab, Rituximab in combination with placebo |
| Enrollment | 340 |
| Start date | Sep 1, 2006 |
| Primary completion | Jan 1, 2010 |
| Completion | Apr 1, 2010 |
| First posted | Aug 15, 2006 |
| Last update posted | Oct 2, 2015 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: